EFFECT OF CRYOPRESERVED PLACENTAL EXPLANTS ON THE COURSE OF EXPERIMENTAL POLYCYSTIC OVARY SYNDROME

Prokopiuk V. Y., Goltsev A. M., Prokopiuk O. S., Somova K. V., Loginova O. O.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Polycystic ovary syndrome (POS) is diagnosed in 5-15% of women in reproductive age. It manifests in anovulation, hyperandrogenism, infertility and carbohydrate metabolism failure. These processes changing during pregnancy, stem cell therapy. It can be supposed, that placental derivatives may be used for POS treatment. The aim of the workwas to study the effect of cryopreserved placental explants (CPE) on the progression of experimental POS. Methods.POS was modeled on Wistar rats by the mefipristone injection. Animals were divided into three groups: 1 –animal with the model of POS without treatment, 2 – animal with POS, treated by 70 mg of CPE, 3 –intact animals. Morphological changes in ovaries, uterus, reproductive indices was studied. Results.A month after POS modeling, all experimental animal had an estrogenic type of vaginal cytology with superficial epithelial cells. Animal without treatment had cystic changes in the ovaries. In some cases, large cysts – up to 5 mm, sometimes the cysts reached 2-3 mm, with a hemorrhages in the cavity. Also were noticed the reducing number of secondary follicles (in the growth stage) and yellow bodies. The number of primordial and primary follicles did not change. The hyperplasia of endometrium was noticed in the uterus. None of animals became pregnant. The presence of a small number of yellow bodies in the ovaries could be explained by luteinisation without ovulation or unavailability of endometrium to implantation. When study the group with POS, treated by CPE, the number of ovarian cysts was significantly lower, the number of yellow bodies and secondary follicles were increased, that indicate some normalization of folliculogenesis. The hyperplasia of endometrium were decreased. Animals with POS, treated by CPE were pregnant in half of the cases. In pregnant animals, the number of yellow bodies, implantation sites, and the number of live fetuses were reduced in comparison with intact animals. However, the greatest difference was in the number of yellow bodies and implantation sites indicates reproductive loss at the implantation stage due to the lack of endometrium preimplantation preparedness. Conclusions.The study suggests that the use of cryopreserved placental explants in the anti-progestin model of POS allows restore of folliculogenesis, endometrium structure and fertility.

polycystic ovary syndrome, placenta, cryopreservation, rats, infertility

1. Nasadyuk KM. Kletochnyye tekhnologii v reproduktologii, akusherstve i ginekologii. Klítinna ta organna transplantologíya. 2013;1(1):56-60.[in Russiаn].
2. Prokopyuk VYu, Prokopyuk OS, Musatova IB, Shevchenko NA, Royenko AA, Terekhova YeA, i dr. Otsenka sokhrannosti eksplantov platsenty i plodnykh obolochek posle kriokonservirovaniya. Klítinna ta organna transplantologíya. 2015;3(1):28-33. [in Russiаn].
3. Stefanov OV, redaktor. Doklíníchní doslídzhennya líkars’kikh zasobív: metod. rekomendatsíí̈ . Kií̈ v: Avítsena; 2001. 528 s. [in Ukrainian].
4. Trifonov VYu, Prokopyuk VYu, Prokopyuk OS, Lipina OV, Volina VV, Zub LI, i dr. Eksperimental’noye obosnovaniye vozmozhnosti pregravidarnoy profilaktiki antifosfolipidnogo sindroma. Tavricheskiy mediko-biologicheskiy vestnik. 2010;13(4):188-92. [in Russiаn].
5. Azziz R. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):781-5. DOI: 10.1210/jc.2005-2153 
6. Giwa S, Lewis JK, Alvarez L, Langer R, Roth AE, Church GM,et al. The promise of organ and tissue preservation to transform medicine. Nat Biotechnol. 2017 Jun 7;35(6):530-42. DOI: 10.1038/nbt.3889
7. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011 Mar;5(1):94-100. DOI: 10.1007/s11684-011-0116-z. Epub 2011 Mar 17.
8. Nishi K, Gunasekaran VP, Arunachalam J, Ganeshan M. Doxorubicin-induced female reproductive toxicity: an assessment of ovarian follicular apoptosis, cyclicity and reproductive tissue histology in Wistar rats. Drug Chem Toxicol. 2018 Jan;41(1):72-81. DOI: 10.1080/01480545.2017.1307851 
9. Prokopyuk VYu, Grischenko OV, Prokopyuk OV, Shevchenko NO, Falko OV, Storchak AV,et al. Effect of cryopreserved placental explants on female reproductive system under normal and pathological conditions (experimental study). Probl.Cryobiol Cryomed. 2017;28(3):250-65.
10. Rasquin LL, Mayrin JV. Polycystic Ovarian Disease (Stein-Leventhal Syndrome). Authors Source StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017-2017 Oct 6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29083730
11. Ruiz A, Aguilar R, Tébar AM, Gaytán F, Sánchez-Criado JE. RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies. Biol Reprod. 1996 Dec;55(6):1284-91.
12. Silini AR, Cargnoni A, Magatti M, Pianta S, Parolini O. The long path of human placenta, and its derivatives, in regenerative medicine. Front Bioeng Biotechnol. 2015 Oct 19;3:162. DOI: 10.3389/fbioe.2015.00162
13. Xiao GY, Liu IH, Cheng CC, Chang CC, Lee YH, Cheng WT, et al. Amniotic fluid stem cells prevent follicle atresia and rescue fertility of mice with premature ovarian failure induced by chemotherapy PLoS One. 2014 Sep 8;9(9):e106538. DOI: 10.1371/journal.pone.0106538
14. Yau TT, Ng NY, Cheung LP, Ma RC. Polycystic ovary syndrome: a common reproductive syndrome with long-term metabolic consequences. Hong Kong Med J. 2017 Dec;23(6):622-34. DOI: 10.12809/hkmj176308

«Bulletin of problems biology and medicine» Issue 1 Part 1 (142), 2018 year, 167-171 pages, index UDK 618.11-006.2: 615.361.013.85.014.41

10.29254/2077-4214-2018-1-1-142-167-171